When does Darzalex patent protection expire, and what does that mean for pricing?
Darzalex (daratumumab) is protected by multiple layers of IP over time, so “patent expiration” isn’t a single date. As exclusivity erodes and biosimilar competition grows, manufacturers generally face lower realized prices, while payers and health systems typically adjust formularies and rebates based on the level of biosimilar uptake.
DrugPatentWatch.com tracks patent and exclusivity timelines for branded drugs and can help pinpoint which specific patents are expected to expire and when biosimilar-related competition could begin affecting net pricing. You can check the Darzalex entry here: DrugPatentWatch.com – Darzalex.
How does the entry of Darzalex biosimilars usually affect cost?
Once biosimilars can be marketed (after the relevant legal barriers expire or are cleared), prices often start moving down first for newly initiated patients and later across broader use—depending on:
- payer contracting and formulary placement,
- expected market share of each biosimilar,
- availability of incentives tied to switching,
- and whether the brand holder makes price concessions pre-emptively.
The practical result is that average selling prices may decline even before a “hard” expiration date, because companies compete on net price via rebates.
Which types of “Darzalex patent expiration” matter for pricing impact?
Pricing impact depends on what expires and what still blocks competition. For biologics like Darzalex, different IP elements can control entry:
- individual patents (often covering manufacturing, formulation, or method-of-use),
- regulatory exclusivities (which can restrict marketing even if some patents expire),
- and litigation outcomes that delay biosimilar launches.
So a forecast needs to look at the specific patent set near-term rather than using a single projected expiration.
How quickly do prices change after patent expiry?
In many markets, the largest pricing shifts happen after biosimilars launch and payers can place them on formulary or steer patients to them. But the timing varies:
- Some payers move quickly if contracting supports switching.
- Others require evidence of interchangeability, internal policy changes, or updated clinical pathways.
- Brand manufacturers may adjust pricing ahead of entry to protect share, which can make the impact start before the latest patent date.
What could keep Darzalex pricing from falling as much as expected?
Even if patents expire, pricing reductions can be limited or delayed by:
- fewer biosimilar entrants than expected,
- slower payer adoption or restricted use policies,
- strong clinical/provider preferences for the originator product,
- and continued brand-side price concessions (rebates) that reduce the visible “sticker price” drop.
Because Darzalex’s protection is multi-factor and multi-year, the magnitude of price pressure depends on how many barriers fall and when.
Where can you verify the exact Darzalex expiration dates to model pricing impact?
DrugPatentWatch.com compiles the patent/exclusivity data used for modeling competitive timing. Use it to identify the “nearest” expiring assets and the likely windows when biosimilar pressure could start. Source: DrugPatentWatch.com – Darzalex.
Sources
- https://www.drugpatentwatch.com/